



Statement in Support of: “Virology under the Microscope—a Call for Rational Discourse”

id Peter Speck,^a Secretary, Australasian Virology Society, **id** Jason Mackenzie,^b Treasurer, Australasian Virology Society, **id** Rowena A. Bull,^c Vice President, Australasian Virology Society, Barry Slobedman,^d Heidi Drummer,^e President, Australasian Virology Society, **id** Johanna Fraser,^f **id** Lara Herrero,^g Karla Helbig,^h **id** Sarah Londrigan,^b **id** Gregory Moseley,^f Natalie Prow,ⁱ **id** Grant Hansman,^g Robert Edwards,^a Chantelle Ahlenstiel,^c Allison Abendroth,^d **id** David Tscharke,^j Jody Hobson-Peters,^k Robson Kriiger-Loterio,^f **id** Rhys Parry,^k Glenn Marsh,^l Emma Harding,^m **id** David A. Jacques,ⁿⁿ Matthew J. Gartner,^b Wen Shi Lee,^b Julie McAuley,^b **id** Paola Vaz,ⁿ Frank Sainsbury,^o **id** Michelle D. Tate,^{r,p} Jane Sinclair,^k Allison Imrie,^q Stephen Rawlinson,^f Andrew Harman,^{d,r} **id** Jillian M. Carr,^a Ebony A. Monson,^h Merilyn Hibma,^s **id** Timothy J. Mahony,^k Thomas Tu,^{d,r} Robert J. Center,^e Lok Bahadur Shrestha,^c Robyn Hall,^{t,u} Morgyn Warner,^{v,w} Vernon Ward,^x Danielle E. Anderson,^b Nicholas S. Eyre,^a Natalie E. Netzler,^{y,z} Alison J. Peel,^o Peter Revill,^{aa} **id** Michael Beard,^v Alistair R. Legione,ⁿ Alexandra J. Spencer,^{bb} Adi Idris,^{cc,g} Jade Forwood,^{dd} **id** Subir Sarker,^h **id** Damian F. J. Purcell,^b Past President, Australasian Virology Society, Nathan Bartlett,^{bb} Joshua M. Deerain,^b Bruce J. Brew,^{m,ee,ff} **id** Sassan Asgari,^k **id** Helen Farrell,^k **id** Alexander Khromykh,^k **id** Daniel Enosi Tuipulotu,^j David Anderson,^e Sevim Mese,^{gg,k} Yaman Tayyar,^{g,hh} Kathryn Edenborough,^f Jasim Muhammad Uddin,ⁱⁱ Abrar Hussain,^{jj} Connor J. I. Daymond,^b Jacinta Agius,^h **id** Karyn N. Johnson,^k Paniz Shirmast,^g Mahdi Abedinzadeshahri,^{oo} Robin MacDiarmid,^{pp} Caroline L. Ashley,^d Jay Laws,^h **id** Lucy L. Furfaro,^q Thomas D. Burton,^a Stephen M. R. Johnson,^a Zahra Telikani,ⁿ Mary Petrone,^d Justin A. Roby,^{dd} Carolyn Samer,^d **id** Andreas Suhrbier,^{k,kk} April Van Der Kamp,^a Anthony Cunningham,^{d,r} Celeste Donato,^{ll} Jackie Mahar,^d Wesley D. Black,^{mm} **id** Subhash Vasudevan,ⁿⁿ Roman Lenchine,^a Kirsten Spann,^{cc} **id** Daniel J. Rawle,^{kk} Penny Rudd,^g Jessica Neil,^b **id** Richard Kingston,^y Timothy P. Newsome,^d Ki Wook Kim,^m Johnson Mak,^g Kym Lowry,^k Nathan Bryant,^{bb} Joanne Meers,^k Jason A. Roberts,^{b,aa} Nigel McMillan,^g Larisa I. Labzin,^k Andrii Slonchak,^k Leon E. Hugo,^{kk} Bennett Henzeler,^s Natalee D. Newton,^k Cassandra T. David,^f **id** Patrick C. Reading,^{qq,n} Camille Esneau,^{bb} Tatiana Briody,^k Najla Nasr,^{r,d} Donna McNeale,^o Brian McSharry,^{dd} Omid Fakhri,^u Bethany A. Horsburgh,^c Grant Logan,^{rr} Paul Howley,^{ss} Paul Young^k

^aFlinders University, Bedford Park, South Australia

^bDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute, Melbourne, Victoria, Australia

^cKirby Institute, University of New South Wales, Sydney, Australia

^dThe University of Sydney, New South Wales, Australia

^eBurnet Institute, Melbourne, Victoria, Australia

^fMonash University, Melbourne, Victoria, Australia

^gGriffith University, Southport, Queensland, Australia

^hLa Trobe University, Melbourne, Victoria, Australia

ⁱHull York Medical School, University of York, York, United Kingdom

^jAustralian National University, Canberra, Australian Capital Territory, Australia

^kUniversity of Queensland, St. Lucia, Queensland, Australia

^lCommonwealth Scientific and Industrial Research Organisation, Geelong, Victoria, Australia

^mUniversity of New South Wales, Sydney, New South Wales, Australia

ⁿUniversity of Melbourne, Melbourne, Victoria, Australia

^oGriffith University, Nathan, Queensland, Australia

^pHudson Institute of Medical Research, Clayton, Victoria, Australia

^qUniversity of Western Australia, Perth, Western Australia, Australia

^rWestmead Institute for Medical Research, Westmead, New South Wales, Australia

^sUniversity of Otago, Dunedin, New Zealand

^tAusvet Pty Ltd., Canberra, Australian Capital Territory, Australia

^uCommonwealth Scientific and Industrial Research Organisation, Black Mountain, Australian Capital Territory, Australia

^vUniversity of Adelaide, Adelaide, South Australia, Australia

^wSA Pathology, Adelaide, South Australia, Australia

^xUniversity of Otago, Dunedin, New Zealand

^yUniversity of Auckland, Auckland, New Zealand

^zMaurice Wilkins Centre of Research Excellence, Auckland, New Zealand

Copyright © 2023 Speck et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Peter Speck, peter.speck@flinders.edu.au.

The authors declare a conflict of interest. P. Speck owns shares in DFU Solutions Pty Ltd. D. Tscharke is a paid consultant of Sementis Ltd. A. Spencer is a contributor to intellectual property licensed by Oxford University Innovation to AstraZeneca. P. Howley is co-founder, shareholder and managing director of VAXMED Pty Ltd., and an inventor of intellectual property owned by Sementis Ltd and VAXMED Pty Ltd. N. Prow is a paid consultant of VAXMED Pty Ltd.

Ed. Note: This letter is being published by the following ASM journals: *Journal of Virology*, *mBio*, and *mSphere*.

Published 25 April 2023

^{aa}Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia

^{bb}The University of Newcastle, Newcastle, New South Wales, Australia

^{cc}Queensland University of Technology, Brisbane, Queensland, Australia

^{dd}Charles Sturt University, Wagga Wagga, New South Wales, Australia

^{ee}University of Notre Dame, Sydney, New South Wales, Australia

^{ff}St. Vincent's Hospital, Sydney, New South Wales, Australia

^{gg}Istanbul University, Istanbul, Turkey

^{hh}Prorenata Biotech, Moledinar, Queensland, Australia

ⁱⁱMurdoch University, Murdoch, Western Australia, Australia

^{jj}Balochistan University of Information Technology, Engineering and Management Sciences, Quetta, Pakistan

^{kk}QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia

^{ll}Murdoch Children's Research Institute, Melbourne, Victoria, Australia

^{mm}Biotopia Environmental Assessment Pty Ltd., Melbourne, Victoria, Australia

ⁿⁿDuke-NUS Medical School, Singapore

^{oo}Islamic Azad University, Mashhad, Iran

^{pp}The New Zealand Institute for Plant & Food Research Limited, Auckland, New Zealand

^{qq}WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia

^{rr}Children's Medical Research Institute, Westmead, NSW, Australia

^{ss}Vaxmed Pty Ltd., Berwick, Victoria, Australia

KEYWORDS COVID-19, SARS-CoV2, biosafety, coronavirus, gain of function, pandemic, zoonosis

We, members of the Australasian Virology Society, agree with and support the statement entitled "Virology under the Microscope—a Call for Rational Discourse" (1). Like virologists everywhere, we have worked with scientist and clinician colleagues worldwide to develop knowledge, tests, and interventions which collectively have reduced the number of deaths due to COVID-19 and curtailed its economic impact. Such work adds to the extraordinary achievements resulting from virology research that have delivered vaccines and/or antivirals against a long list of diseases and global scourges, including AIDS, smallpox, and polio (1).

We believe the question of the origin of SARS-CoV-2 should be approached with an open mind and in consideration of the best scientific evidence available. We concur with the view that the zoonosis hypothesis has the strongest supporting evidence (2–4), and this is a scenario that has been observed repeatedly in the past (5), including in Australia (6). Recent data strongly support the zoonosis hypothesis (7). We share the concern that emotive and fear-based dialogues in this area add to public confusion and can lead to ill-informed condemnation of virology research.

We believe the current narrative used by some parties—that gain-of-function research is synonymous with high-risk or nefarious activity—fails to appreciate, first, the true scientific value of this legitimate approach to experimental design and, second, the strength and effectiveness of current regulations. There is an extensive history of gain-of-function research safely and effectively contributing to the development of vaccines and antivirals (1). A recent review of gain-of-function studies conducted by the Australian Government defined gain-of-function research as "a change to the genome of any biological entity—a living organism such as an animal, insect, plant, virus, bacterium, or fungus—through any process so that it acquires a new or enhanced function". The review concluded that oversight of gain-of-function research in Australia is comprehensive and robust (8).

We do not believe virology research needs additional legislative controls. As in the United States, regulations in our region applying to virology research are strong, effective, and provide powerful oversight of manipulations of viruses by researchers. We support the call to legislators to resist fear-based campaigns that might lead to unnecessary and counter-productive restrictions being placed on virology research and may limit progress toward new antiviral drugs and vaccines.

We echo the call for policy makers, virologists, and biosafety experts to work together to ensure that research is conducted safely, with the common goal of reducing the burden of disease caused by viruses.

ACKNOWLEDGMENTS

The opinions expressed reflect those of the authors and not necessarily those of the authors' institutions or funding agencies. No funding was used to support this commentary, but we wish to disclose funding from agencies received by authors. Flinders University: P.S.; La Trobe University: K.H.; Diabetes Australia: P.S.; Australian Government National Health and Medical Research Council: P.S., J.F., A.A., K.H., L.H., B.S., S.L., D.C.T., D.A.J., J.M., A.H., J.M.C., M.W., N.S.E., M.B., B.J.B., Y.T., L.L.F., K.W.K., L.I.L., and N.D.N.; Australian Research Council: J.F., R.E., D.C.T., D.A.J., P.V., F.S., S.S., J.M., and L.I.L.; Fisheries Research and Development Corporation: K.H. and P.S.; Victorian Medical Research Acceleration Fund: H.D.; Medical Research Future Fund: H.D., and Y.T.; mRNA Victoria: H.D.; United States NIH: R.E.; Australian National University: D.C.T.; DMTC: D.C.T.; Advance Queensland: J.H.P.; CSIRO: G.M., F.S., and D.M.; Wellcome Trust: D.A.J.; UNSW: D.A.J.; University of Melbourne: W.S.L. and P.V.; Medical Research Future Fund: J.M.; Channel 7 Children's Research Foundation: J.M.C.; New Zealand Ministry for Business Innovation and Employment: V.W.; Health Research Council of New Zealand: N.E.N.; Innovation and Technology Commission, Hong Kong Special Administrative Region, China: M.P.; Department of Education Regional Research Collaboration Grant, Training Hub promoting Regional Industry and Innovation in Virology and Epidemiology (THRIVE), J.A.R.; Juvenile Diabetes Research Foundation: K.W.K.; University of Queensland: K.L.

REFERENCES

1. Goodrum F, Lowen AC, Lakdawala S, Alwine J, Casadevall A, Imperiale MJ, Atwood W, Avgousti D, Baines J, Banfield B, Banks L, Bhaduri-McIntosh S, Bhattacharya D, Blanco-Melo D, Bloom D, Boon A, Boulant S, Brandt C, Broadbent A, Brooke C, Cameron C, Campos S, Caposio P, Chan G, Cliffe A, Coffin J, Collins K, Damania B, Daugherty M, Debbink K, DeCaprio J, Dermody T, Dikeakos J, DiMaio D, Dinglasan R, Duprex WP, Dutch R, Elde N, Emerman M, Enquist L, Fane B, Fernandez-Sesma A, Flenniken M, Frappier L, Frieman M, Frueh K, Gack M, Gaglia M, Gallagher T, Galloway D, et al. 2023. Virology under the microscope—a call for rational discourse. *J Virol* 97:e00089-23. <https://doi.org/10.1128/jvi.00089-23>.
2. Holmes EC, Goldstein SA, Rasmussen AL, Robertson DL, Crits-Christoph A, Wertheim JO, Anthony SJ, Barclay WS, Boni MF, Doherty PC, Farrar J, Geoghegan JL, Jiang XW, Leibowitz JL, Neil SJD, Skern T, Weiss SR, Worobey M, Andersen KG, Garry RF, Rambaut A. 2021. The origins of SARS-CoV-2: a critical review. *Cell* 184:4848–4856. <https://doi.org/10.1016/j.cell.2021.08.017>.
3. Garry RF. 2022. The evidence remains clear: SARS-CoV-2 emerged via the wildlife trade. *Proc Natl Acad Sci USA* 119. <https://doi.org/10.1073/pnas.2214427119>.
4. Alwine JC, Casadevall A, Enquist LW, Goodrum FD, Imperiale MJ. 2023. A critical analysis of the evidence for the SARS-CoV-2 origin hypotheses. *J Virol* 0:e00365-23.
5. Plowright RK, Parrish CR, McCallum H, Hudson PJ, Ko AI, Graham AL, Lloyd-Smith JO. 2017. Pathways to zoonotic spillover. *Nat Rev Microbiol* 15: 502–510. <https://doi.org/10.1038/nrmicro.2017.45>.
6. Mahalingam S, Herrero LJ, Playford EG, Spann K, Herring B, Rolph MS, Middleton D, McCall B, Field H, Wang LF. 2012. Hendra virus: an emerging paramyxovirus in Australia. *Lancet Infect Dis* 12:799–807. [https://doi.org/10.1016/S1473-3099\(12\)70158-5](https://doi.org/10.1016/S1473-3099(12)70158-5).
7. Crits-Christoph A, Gangavarapu K, Pekar JE, Moshiri N, Singh R, Levy JI, Goldstein SA, Suchard MA, Popescu S, Robertson DL, Lemey P, Wertheim JO, Garry RF, Rasmussen AL, Andersen KG, Holmes EC, Rambaut A, Worobey M, Débarre Florence. 2023. Genetic evidence of susceptible wildlife in SARS-CoV-2 positive samples at the Huanan Wholesale Seafood Market, Wuhan: Analysis and interpretation of data released by the Chinese Center for Disease Control. <https://zenodo.org/record/7754299#.ZBsVyfZBycF>.
8. Australian Government. 2022. Research Review Report. Australian Government, Canberra, Australia. Accessed March 25 2023.